Answers are grounded in this paper and cite their sources.
A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.
No takes yet. Share an insight, caveat, or question.
Forbes et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: